Mark Yen

976 total citations
18 papers, 448 citations indexed

About

Mark Yen is a scholar working on Molecular Biology, Genetics and Pharmacology. According to data from OpenAlex, Mark Yen has authored 18 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Genetics and 3 papers in Pharmacology. Recurrent topics in Mark Yen's work include Inflammatory Bowel Disease (4 papers), Alzheimer's disease research and treatments (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Mark Yen is often cited by papers focused on Inflammatory Bowel Disease (4 papers), Alzheimer's disease research and treatments (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Mark Yen collaborates with scholars based in United States, United Kingdom and Canada. Mark Yen's co-authors include Michael N. Hartnett, M C Champion, James J. Keirns, Salim Mujais, Donna Kowalski, Larry Ereshefsky, Atsunori Kaibara, E. Marcel van Gelderen, Marloes Schaddelee and Marek Malík and has published in prestigious journals such as Gastroenterology, Antimicrobial Agents and Chemotherapy and The American Journal of Gastroenterology.

In The Last Decade

Mark Yen

17 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Yen United States 8 130 101 89 66 65 18 448
Adriana Pedreáñez Venezuela 13 80 0.6× 105 1.0× 76 0.9× 29 0.4× 92 1.4× 43 540
Alan J. Tuchman United States 11 68 0.5× 83 0.8× 35 0.4× 70 1.1× 52 0.8× 22 447
Lujin Li China 12 57 0.4× 37 0.4× 22 0.2× 76 1.2× 91 1.4× 65 531
Curtis Vande Stouwe United States 16 95 0.7× 42 0.4× 83 0.9× 247 3.7× 155 2.4× 22 626
Sailesh Harwani United States 9 84 0.6× 91 0.9× 40 0.4× 30 0.5× 103 1.6× 12 581
Kirk J. Pak United States 10 40 0.3× 85 0.8× 17 0.2× 20 0.3× 65 1.0× 11 325
J Fakhry United States 12 92 0.7× 51 0.5× 39 0.4× 11 0.2× 75 1.2× 20 464
Susan E. Wozniak United States 9 214 1.6× 196 1.9× 9 0.1× 50 0.8× 96 1.5× 19 602
Bonifacio Alvarez‐Lario Spain 10 66 0.5× 49 0.5× 13 0.1× 32 0.5× 165 2.5× 24 591
Hilary Faust United States 10 79 0.6× 61 0.6× 43 0.5× 16 0.2× 160 2.5× 26 597

Countries citing papers authored by Mark Yen

Since Specialization
Citations

This map shows the geographic impact of Mark Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yen more than expected).

Fields of papers citing papers by Mark Yen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yen. The network helps show where Mark Yen may publish in the future.

Co-authorship network of co-authors of Mark Yen

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Yen. A scholar is included among the top collaborators of Mark Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Yen. Mark Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Sands, B E, et al.. (2025). P0580 Efficacy and safety results of tulisokibart re-induction treatment in participants with ulcerative colitis in the Phase 2 ARTEMIS-UC clinical trial. Journal of Crohn s and Colitis. 19(Supplement_1). i1158–i1159. 1 indexed citations
2.
3.
4.
5.
Eidson, Lori N., George T. Kannarkat, Christopher J. Barnum, et al.. (2017). Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease. Journal of Neuroinflammation. 14(1). 164–164. 69 indexed citations
6.
Keirns, James J., Amit Desai, Donna Kowalski, et al.. (2017). QT Interval Shortening With Isavuconazole:In VitroandIn VivoEffects on Cardiac Repolarization. Clinical Pharmacology & Therapeutics. 101(6). 782–790. 59 indexed citations
7.
Owens, Robert C., et al.. (2015). Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clinical Drug Investigation. 35(12). 785–793. 15 indexed citations
8.
Martin, Paul, S.Y. Amy Cheung, Mark Yen, David Han, & Michael Gillen. (2015). Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies. European Journal of Clinical Pharmacology. 72(1). 61–71. 9 indexed citations
9.
Pan, Wei‐Jian, Barbara Sullivan, William A. Rees, et al.. (2013). Sa1206 Multiple-Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of AMG 181, a Human Anti-a4β7 Antibody for Treating Inflammatory Bowel Diseases (IBD). Gastroenterology. 144(5). S–229. 1 indexed citations
10.
Malík, Marek, E. Marcel van Gelderen, Donna Kowalski, et al.. (2012). Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study. Clinical Pharmacology & Therapeutics. 92(6). 696–706. 112 indexed citations
11.
Lai, Robert, Bruce Albala, June Kaplow, et al.. (2012). O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing. Alzheimer s & Dementia. 8(4S_Part_3). 46 indexed citations
12.
Pan, Wei‐Jian, Barbara Sullivan, Sonal Patel, et al.. (2012). Su2082 Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Amg 181, a Fully Human Anti-α4β7 Antibody for Treating Inflammatory Bowel Diseases (IBD). Gastroenterology. 142(5). S–565. 1 indexed citations
13.
Martényi, Ferenc, Stephen L. Lowe, Robert A. Dean, et al.. (2010). P4‐088: Central and Peripheral Pharmacokinetic and Pharmacodynamic Effects of the β‐site APP Cleavage Enzyme (BACE1) Inhibitor LY2811376 In Humans. Alzheimer s & Dementia. 6(4S_Part_21). 6 indexed citations
14.
Ereshefsky, Larry, et al.. (2009). P3‐243: The role for CSF dynabridging studies in developing new therapies for Alzheimer's disease. Alzheimer s & Dementia. 5(4S_Part_14). 5 indexed citations
15.
Ereshefsky, Larry, et al.. (2009). Cerebrospinal Fluid β-Amyloid and Dynabridging in Alzheimer's Disease Drug Development. Biomarkers in Medicine. 3(6). 711–721. 6 indexed citations
16.
Jhee, S. S., Mark Yen, Larry Ereshefsky, et al.. (2008). Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers. Antimicrobial Agents and Chemotherapy. 52(10). 3687–3693. 47 indexed citations
17.
Champion, M C, Michael N. Hartnett, & Mark Yen. (1986). Domperidone, a new dopamine antagonist.. PubMed. 135(5). 457–61. 68 indexed citations
18.
Morgan, R. L., George E. Burrows, Mark Yen, & James L. Way. (1982). Metabolic disposition of the alkylphosphate antagonist, 1,1'-trimethylenebis(4-aldoximinopyridinium) ion (TMB-4), in the rat. III. Trimethylene-1-(4-aldoximinopyridinium)-1'-(4-carboxamidopyridinium) ion.. Drug Metabolism and Disposition. 10(5). 491–494. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adriana Pedreáñez Breakdown of academic impact, for papers by Alan J. Tuchman Breakdown of academic impact, for papers by Lujin Li Breakdown of academic impact, for papers by Curtis Vande Stouwe Breakdown of academic impact, for papers by Sailesh Harwani Breakdown of academic impact, for papers by Kirk J. Pak Breakdown of academic impact, for papers by J Fakhry Breakdown of academic impact, for papers by Susan E. Wozniak Breakdown of academic impact, for papers by Bonifacio Alvarez‐Lario Breakdown of academic impact, for papers by Hilary Faust
Rankless by CCL
2026